BTK and primary central nervous system lymphoma: Pirtobrutinib, the only approved third-generation noncovalent BTK inhibitor, is used to treat R/R lymphomas after at least two lines of prior systemic therapy, and the effectiveness and efficacy of noncovalent BTK inhibitors in treating PCNSL remain unknown.